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Diabetic db/db mice exhibit central nervous system
and peripheral molecular alterations as seen in
neurological disorders
A Ernst1, AN Sharma2, KM Elased2, PC Guest1, H Rahmoune1 and S Bahn1,3
The db/db mouse is a widely used preclinical model in diabetes research. Recent studies have shown that these mice also
display aspects of psychosis and depression-like behaviors as seen in some psychiatric disorders. Here, we have performed
multiplex immunoassay and liquid chromatography mass spectrometry profiling of the plasma and brain samples from db/db
and control mice to identify altered pathways, which could be related to these behavioral abnormalities. This is the first study to
carry out profiling of the brain proteome in this model. Plasma from the db/db mice had increased levels of leptin and insulin,
decreased levels of peptide YY, glucagon and prolactin and alterations in inflammation-related proteins, compared with control
mice. Frontal cortex tissue from the db/db mice showed changes in proteins involved in energy metabolism, cellular structure
and neural functioning, and the hippocampus had changes in proteins involved in the same pathways, with additional effects on
cellular signalling proteins. The overlap of these findings with effects seen in type 2 diabetes, schizophrenia, major depressive
disorder and Alzheimer’s disease might contribute to a common endophenotype seen in metabolic and neurological disorders.
Translational Psychiatry (2013) 3, e263; doi:10.1038/tp.2013.42; published online 28 May 2013
Introduction
The link between metabolic conditions such as diabetes and
psychiatric disorders has been reported widely.1 In most
cases, metabolic abnormalities have been identified in
association with psychiatric disorders as a side effect induced
by commonly prescribed anti-psychotic medications.2 How-
ever, recent studies have shown that such changes can occur
at disease onset even before medications have been applied.
For example, hyperinsulinemia and insulin resistance have
been reported in first onset, antipsychotic naive schizophrenia
patients in several studies over the past decade.3,4 This
indicates that there may be an etiological link between
metabolic and psychiatric conditions, which could be an
important consideration in downstream treatment approaches.
The db/db mouse has been used as a model of type 2
diabetes mellitus and other metabolic conditions, such as
obesity and dyslipidemia.5 This model was first described in
1965 by Hummel et al.,6 who identified random mutations in
mice associated with obesity and excessive hunger. The models
were later segregated as ob/ob mice with gene mutations for
leptin, and db/db mice that have mutations for the gene encoding
the long isoform of the leptin receptor, localized mainly in the
hypothalamic region of the brain.7 The db/db mouse model
mirrors the clinical picture of type 2 diabetes mellitus.
A recent study found that hippocampal inflammation in
db/db mice is associated with increased anxiety-like
behavior.8 It has been reported that patients with diabetes
have an increased probability of developing major depressive
disorder9 and Alzheimer’s disease or cognitive impairments10
compared with non-diabetic people. It has also been
suggested that type 2 diabetes and Alzheimer’s disease
share similar biochemical and molecular features.11 Consis-
tent with the link between psychiatric and metabolic disorders,
recent studies have shown that db/db mice exhibit behavioral
abnormalities, such as impairments in memory function and
long-term potentiation, as well as depression and psychosis-
like behaviors.12,13 Furthermore, treatment of db/db mice with
anti-diabetic medications such as rosiglitazone has led to
improved insulin signalling along with a decrease in measures
of depression but not in psychosis-like behaviors.14
In this study, we have carried out molecular profiling of
plasma samples from db/db mice in order to identify peripheral
molecular pathways, which are altered in this model. In
addition, we have carried out the first proteomic profiling
analysis of brain tissues from these mice in order to gain
insight into the altered molecular pathways associated with
the observed schizophrenia- and depression-like behaviors.
Materials and methods
Animals. Male db/db mice (10-week old; background
strain C57BL/KsJ (BKS-Cg-Dock7m þ /þ Leprdb/J)) and
age-matched non-diabetic lean control C57BL/KsJ mice
(Jackson Laboratories; Bar Harbor, ME, USA) were housed
singly in plastic cages with wooden shavings in a tempera-
ture controlled room (22–23 1C) on a 12-h/12-h light/dark
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cycle (lights on at 0500 hours) (Table 1). Single housing of
db/db mice is routinely practiced in our lab and by most of the
labs worldwide. Housing at this temperature range results in
no change in diurnal rhythm of db/db mice compared with
control mice.15 To assess the metabolic status of the mice,
body weight, food consumption and water intake were
monitored weekly (Table 2). Blood samples were taken from
a cut made on the tip of the tail from each mouse and glucose
concentrations were determined using an Accu-Check
Advantage Blood Glucose Monitor (Roche Diagnostic Cor-
poration, Indianapolis, IN, USA) to confirm development of
diabetes in db/db mice compared with that in lean controls.
Body fat composition was measured as described pre-
viously.13 The EchoMRI whole-body composition analyzer
(Houston, TX, USA) was used to determine fat and lean body
mass.16 Fat and lean mass were calculated as percentage of
total mass. A total of 20 mice (10 db/db and 10 lean control
mice) were killed according to schedule 1, decapitated and
trunk blood was collected in ice-chilled tubes containing
EDTA and centrifuged at1100 g, 4 1C for 15 min. Plasma was
immediately separated and stored frozen at  80 1C for later
use. Frontal cortex and hippocampal regions of the brain
were dissected on ice and immediately frozen at  80 1C. All
experiments were carried out in full compliance with the
principles of laboratory animal care (NIH publication no. 85–
23, revised 1985), and the protocols were approved by the
Wright State University Animal Care and Use Committee.
Plasma insulin measurements. Plasma insulin levels
were determined at Mouse Metabolic Phenotyping Centre
(Cincinnati, OH, USA) by using the commercial immuno-
assay kits (Millipore, St Charles, MO, USA) according to the
manufacturer’s specifications. Briefly, standards, quality
controls and samples were incubated for 2 h in microplate
wells pre-coated with mouse anti-rat insulin antibodies (80ml
per well). After washing, biotin-labeled polyclonal antibodies
were added (100 ml per well) followed by incubation for
30 min. After washing, horse radish peroxidase conjugate
and the substrate 3,3’,5,5’-tetramethylbenzidine solution
(100 ml per well) were added for a 15-min incubation. The
reactions were halted by addition of 100ml per well 0.3 M HCl,
and the absorbance of the resulting color product was
measured at l¼ 450 nm. The concentrations of the experi-
mental samples were determined by comparison of the
absorbance values with those of a standard curve, con-
structed using 0.2, 0.5, 1, 2, 5 and 10 ng ml 1 insulin.
Multiplex immunoassay profiling. Plasma samples were
analyzed using the RodentMAP, Rat MetabolicMAP and Rat
KidneyMAP platforms comprising multiplexed immunoas-
says for a total of 89 analytes (86 proteins and 3 steroid
hormones) (Supplementary Table S1) in a Clinical Labora-
tory Improved Amendments (CLIA)-certified laboratory at
Myriad-RBM (Austin, TX, USA) as described recently.17
Immunoassays were calibrated using duplicate standard
curves for each analayte and raw intensity measurements
converted to protein concentrations using proprietary
software. Multiplexed calibrators (eight levels per analyte)
and controls (three levels per analyte) are developed to
monitor key performance parameters, such as lower limit
of quantification, precision, cross-reactivity, linearity, spike-
recovery, dynamic range, matrix interference, freeze–thaw
stability, and short-term sample stability are established for
every assay as described by the manufacturer (http://www.
myriadrbm.com/technology/data-quality/). Data analyses
were performed using the statistical software package R
(http://www.r-project.org) and the levels of analytes were
determined. Analyses were conducted under blinded condi-
tions with respect to sample identities, and samples were
analyzed in random order to avoid any sequential biases.
Liquid chromatography mass spectrometry (LC-MSE)
profiling. Frontal cortex and hippocampus tissues from db/
db (n¼ 10) and control (n¼ 10) mice were sonicated in a
buffer comprised of 7 M urea, 2 M thiourea, 4% chaps, 2%
ASB14, 70 mM dithiothreitol and protease inhibitors (5:1 (v/w)
ratio) at a 5:1 (v/w) ratio and mixed for 30 min. Samples were
centrifuged for 3 min at 17 000 g at 4 1C and the supernatants
recovered. Protein concentrations of the lysates were
determined using a Bradford assay (Bio-Rad; Hemel
Hempstead, UK). Proteins (approximately 100 mg) were
precipitated using acetone, centrifuged for 3 min at 17 000 g
at 4 1C and the pellets suspended in 50 mM ammonium
bicarbonate. Disulfide bonds were reduced in 5 mM dithio-
threitol at 60 1C for 30 min, and free sulfhydryl groups were
alkylated by incubation in 10 mM iodacetamide in the dark at
37 1C for 30 min. Protein digestion was conducted using
porcine trypsin at a 1:50 (w/w) ratio for 17 h at 37 1C, and
reactions were stopped by addition of 8.8 M HCl at a 1:60
(w/w) ratio. Quality control samples consisting of frontal
cortex and hippocampus protein extracts from a wild-type
mouse were prepared as above and underwent all
experimental steps in parallel with the test samples to
monitor machine performance.
LC-MSE analyses were carried out in triplicate of individual
samples as described previously.18 Samples were diluted in
0.1% formic acid (Sigma-Aldrich; Poole, UK) to a final peptide
concentration of 0.12 mg ml 1 and reverse phase LC separa-
tion was performed using a nanoACQUITY system (Waters
Corporation; Milford, MA, USA) comprised of a C18 trapping
Table 2 Food and water consumption of db/db and control mice
Mouse strain N Food intake
(g per day per mouse)
Water intake
(gper day per mouse)
Lean control 10 3.85±0.11 9.76±0.89
db/db 10 6.74±0.37* 20.15±2.39*
*Po0.05 versus lean control mice, unpaired t-test.
Table 1 Physical and metabolic characteristics of db/db and control mice
Parameter Control db/db
Age (weeks) 10 10
Body weight (g) 25.2±0.6 36.0±1.2*
Blood glucose (mg dl 1) 140.3±8.8 583.2±35.9*
Plasma insulin (ng ml 1) 1.3±0.2 4.6±1.5*
Percentage of fat mass 17.9±1.0 58.9±0.8*
Percentage of lean mass 70.4±1.0 42.7±1.4*
*Po0.05 (unpaired t-test).
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column (180 mm 20 mm; 5 mm particle size) and a C18 BEH
nanocolumn (75 mm 200 mm; 1.7 mm particle size). The
buffers were as follows: (A) H2Oþ 0.1% formic acid and (B)
acetonitrile (Sigma-Aldrich)þ 0.1% formic acid. Initial buffer
concentrations were 3% B (97% A) followed by 3–30% B over
90 min, 30 90% B over 25 min, 90 97% B over 5 min,
constant 97% B for 10 min and 97 3% B over 1 min. The
column was coupled online to a nanoESI emitter on a
quadrupole time-of-flight (Q-TOF Premier) mass spectro-
meter (Waters Corporation). Approximately 500 fmol ml 1 of
Glu Fibrinopeptide B (Waters Corporation) was infused every
30 s using a lock spray for mass calibration. The mass
spectrometer was operated in V mode and analyses were
performed using positive nanoESI ion mode. The collision
energy was 5 eV for low-energy scans and ramped from 17 to
40 eV for high-energy scans with a cycle time of 1.3 s. The low
collision energy generates intact precursor ion data, and the
high collision energy provides information about the peptide
fragments.
Data analysis. Analysis of multiplex immunoassay profiling
data was conducted using nonparametric Wilcoxon rank-sum
tests to account for any uneven distribution of the data.
Po0.05 was considered as statistically significant. LC-MSE
data were processed using ProteinLynx Global Server
(PLGS) v.2.4 (Waters Corporation) and Rosetta Elucidator
v.3.3 (Rosetta Biosoftware; Seattle, WA, USA) for time and
mass/charge alignment of ion fragments as described
previously.18 The Mus musculus complete proteome FASTA
(sourced from www.uniprot.org) sequence Integr8 database
was used for the appropriate protein searches. Acceptable
modifications were set to include oxidation of methionine and
phosphorylation of serine, threonine or tyrosine residues.
The criteria for valid protein identifications were set at a
minimum of three fragment ions/peptide ion and seven
fragment ions/protein and detection of peptides in at least
two out of three replicates. In addition, proteins had to be
identified in 60% of samples to ensure biological reproduci-
bility. The results were imported into Elucidator for alignment
and annotation of the features. The end result was a matrix
that included peptide intensities for each sample. Proteins
identified by X2 peptides were considered for further
analyses (Supplementary Table S2).
Statistical analyses. Significant differences in protein
expression generated by the LC-MSE analyses, between
db/db and control mice, were determined using Wilcoxon
signed-rank tests (Po0.05). The false discovery rate was
calculated, although no adjustments were made for multiple
comparisons in order to not exclude possible true positives.
Nevertheless, only those molecules with a false discovery
rate o0.4 and a fold change cut off of 0.10 for the LC-MSE
analyses were applied in order that only those molecules with
the most robust changes were considered.
Classification of differentially expressed proteins. The
UniProt accession codes of significantly altered proteins
found in brain tissues from db/db and control mice were
uploaded to the Ingenuity Pathway Analysis Knowledge
Base (IPKB; Ingenuity Systems; Mountain View, CA, USA).
Networks and pathways that were most significant to the data
set were determined by overlaying the uploaded proteins
onto predefined pathway maps in the IPKB. A right-tailed
Fisher’s exact test was used to calculate the P-values
associated with the identified canonical pathways.
Results
Plasma analysis. Multiplex immunoassay profiling of
plasma samples showed that 31 molecules were present at
different levels between db/db and control mice (Table 3). As
expected, leptin levels were significantly higher (approxi-
mately 18-fold) in db/db compared with the control mice.
Several other molecules were also present at higher levels in
the db/db mice, including insulin, C-reactive protein, serum
amyloid P component, immunoglobulin A, interleukin 18,
monocyte chemotactic proteins 1 and 3 and fibrinogen.
In addition, other proteins showed decreased levels in the
Table 3 Multiplexed immunoassay of plasma from db/db and control mice
Molecule P-value Ratio Function
mLeptin 0.001 18.68 Hormone
mC-Reactive protein 0.001 2.59 Immune response
mSerum amyloid P
component
0.001 2.07 Immune response
mMyeloperoxidase 0.001 1.90 Enzyme
mPlasminogen activator
inhibitor 1
0.002 1.82 Proteinase
inhibitor
mImmunoglobulin A 0.001 1.80 Immune response
mInterleukin-18 0.012 1.64 Immune response
mInsulin 0.002 1.63 Hormone
mMonocyte chemotactic
protein 1
0.001 1.51 Immune response
mMonocyte chemotactic
protein 3
0.005 1.49 Immune
Response
mMatrix Metalloprotei-
nase 9
0.037 1.33 Enzyme
mFibrinogen 0.042 1.23 Immune response
mFibroblast growth factor
basic
0.032 1.19 Growth factor
mSerum glutamic oxa-
loacetic transaminase
0.019 1.19 Enzyme
.Endothelin-1 0.002 0.79 Vascular
homestasis
.Peptide YY 0.010 0.79 Hormone
.Glucagon 0.003 0.79 Hormone
.Prolactin 0.016 0.76 Hormone
.Monocyte chemotactic
protein 5
0.003 0.73 Immune response
.Apolipoprotein A1 0.001 0.73 Lipid metabolism
.Osteopontin 0.004 0.70 Immune response
.Haptoglobin 0.014 0.70 Immune response
.Cystatin-C 0.005 0.65 Protein
Metabolism
.Stem cell factor 0.004 0.63 Signal
transduction
.Factor VII 0.001 0.62 Enzyme
.Macrophage colony
stimulating factor 1
0.001 0.59 Cell differentiation
.Interleukin-10 0.049 0.53 Immune response
.Epidermal growth factor 0.002 0.51 Growth factor
.Vascular cellular
adhesion molecule 1
0.001 0.48 Signal
transduction
.Beta 2 microglobulin 0.031 0.48 Immune response
.Lymphotactin 0.001 0.41 Immune response
The ratio change was calculated as db/db/control. Functions were assigned
using the Ingenuity Pathway Analysis Knowledge Base software as described in
the Reseach Design and Methods section.
Increased and decreased levels of analytes are represented by green and red
arrows respectively.
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db/db mice peptide YY, glucagon, prolactin, apolipoprotein A,
monocyte chemotactic protein 5, osteopontin, haptoglobin,
interleukin 10, beta 2 microglobulin and lymphotactin.
Frontal cortex analysis. Brain proteome analyses of the
db/db and control mice were performed using LC-MSE to
determine whether changes occurred as described in some
post-mortem studies of neuropsychiatric and neurodegen-
erative diseases. LC-MSE analysis of whole frontal cortex
extracts led to the identification of 478 proteins. Of these
proteins, 13 were found to be significantly altered in db/db
compared with control mice (Table 4). Four of these proteins
were increased and nine decreased. The highest increase
was observed for the insulin-like growth factor 2 mRNA
binding protein 1 and the calcium calmodulin-dependent
protein kinase type II alpha chain (CAMK2A). The most
robust decreases were observed for stathmin 2 and
neuromodulin. In silico functional analysis using the IPKB
software analysis showed that 12 of the 13 altered proteins
could be incorporated into a single interaction network
(Figure 1). The top disease identified with the uploaded
proteins was neurological disorder (P¼ 7.1E-5–4.4E-2) and
Parkinson’s disease-related signalling was the top canonical
pathway (P¼ 7.4E-5; 2/16 proteins).
Hippocampus analysis. Proteome analysis of the hippo-
campus from db/db and control mice led to identification of
441 proteins. Differential analysis showed that more proteins
were altered in this tissue compared with the frontal cortex,
with 56 proteins found to be present at significantly different
levels between db/db and control mice (Table 5). The highest
increases were observed for tubulin beta 5 chain and Thy 1
membrane glycoprotein. The largest decreases were found
for groups of proteins involved in metabolic processes
(malate dehydrogenase mitochondrial, cytochrome b c1
complex subunit 2, malate dehydrogenase cytoplasmic) or
intracellular transport (alpha internexin, heat shock 70 kDa
protein 1L, dihydropyrimidinase related protein 1, ras-related
protein rab 39B). IPKB analysis of the altered proteins
identified a network comprising 14 of the target proteins
(Figure 2). Most of the altered proteins were involved in
cellular signalling, cell structure and maintenance, neural
functioning and energy metabolism. Three members of the
14-3-3 protein family, conserved regulatory molecules
expressed in all eukaryotes, were among the group of
altered proteins. Furthermore, several molecules linked to
regulation of calcium signalling were also altered. The top
disease associated with the altered hippocampal proteins
was hematological disease (P¼ 8.4E-5–1.7E-2) and the top
canonical pathway was clathrin-mediated endocytosis sig-
nalling (P¼ 3.0E-6; 7/181 proteins).
Discussion
This is the first proteomic profiling study investigating plasma
and brain tissues from the db/db mouse model. The
advantage of using the multiplex profiling approach is the
potential to identify differences in hundreds of molecules
simultaneously, which can lead to the identification of changes
in functional pathways. Profiling of plasma from db/db mice
showed the expected robust increase in leptin levels, along
with significantly higher levels of insulin compared with the
levels in control mice. In line with these findings, we also found
decreased levels of other hormones such as peptide YY,
glucagon and prolactin, which suggested that lack of leptin
receptors in the db/db mice can lead to either altered
biosynthesis or secretion of other major hormones.
The use of the multiplex immunoassay profiling analysis
resulted in identification of several novel serum molecules,
which have not been described previously in association with
this model. The finding of lower peptide YY levels is consistent
Table 4 LC-MSE analysis of frontal cortex from db/db and control mice
UniProt Gene Protein Function P-value Ratio
mO88477 IF2B1 Insulin-like growth
factor 2 mRNA-binding
protein 1
Translation 0.016 1.29
mP11798 KCC2A Ca2þ calmodulin dep.
kinase type II a chain
Kinase 0.037 1.25
mQ9Z2Q6 SEPT5 Septin 5 Enzyme 0.035 1.24
mO89053 COR1A Coronin 1A Other 0.030 1.16
.O08709 PRDX6 Peroxiredoxin 6 Enzyme 0.035 1.10
.Q8K183 PDXK Pyridoxal kinase Kinase 0.019 1.11
.P00920 CAH2 Carbonic anhydrase 2 Enzyme 0.038 1.13
.P63085 MK01 Mitogen-activated
protein kinase 1
Kinase 0.007 1.14
.Q02053 UBA1 Ubiquitin-like modifier
activating enzyme 1
Enzyme 0.036 1.14
.Q61171 PRDX2 Peroxiredoxin 2 Enzyme 0.026 1.16
.P55821 STMN2 Stathmin 2 Other 0.043 1.19
.Q61207 SAP Sulfated glycoprotein 1 Other 0.046 1.14
.P06837 NEUM Neuromodulin Other 0.009 1.18
Abbreviations: LC-MSE, liquid chromatography mass spectrometry; UniProt,
UniProt accession code.
Cellular locations and molecular functions were assigned using Ingenuity
Pathway Analysis Knowledge Base. The ratio was calculated as in the legend
for Table 3.
Increased and decreased levels of analytes are represented by green and red
arrows respectively.
Figure 1 In silico functional analysis of proteomic changes in the frontal
cortex of db/db mice. UniProt accession codes were uploaded into the Ingenuity
Pathway Analysis Knowledge Base to determine the most over-represented
networks and canonoical pathways associated with the data. Straight lines¼ direct
connections; dotted lines¼ indirect connections; green colour¼ increased; red
colour¼ decreased.
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with the increased appetite and body weight of the db/db mice
and with previous studies which have shown that obese
humans secrete lower levels of this hormone.19 Lower levels
of peptide YY have also been found in drug-free schizophrenia
patients in a biomarker study of cerebrospinal fluid, suggesting
another link between metabolic regulation and psychiatric
disorders.20 The finding of decreased circulating prolactin levels
in db/db mice has also not been reported previously. Prolactin is
secreted by the anterior pituitary and this process can be
inhibited by release of dopamine from the arcuate nuclease of
the hypothalamus.21 This is interesting as one of the major
theories of how schizophrenia develops involves increased
dopaminergic activity in the brain.22 Therefore, further studies
are warranted to determine whether hypothalamic–pituitary
dopamine signalling is altered in this model.
In addition to the effects on hormonal pathways, we also
identified alterations in immune and inflammation-related
molecules in plasma from db/db mice. Several studies
Table 5 LC-MSE analysis of hippocampus from db/db and control mice
UniProt Gene Protein Function P-value Ratio
mP99024 TBB5 Tubulin beta 5 chain Other 0.031 1.31
mP01831 THY1 Thy 1 membrane glycoprotein Other 0.032 1.29
mP51881 ADT2 ADP ATP translocase 2 Transporter 0.007 1.26
mP68033 ACTC Actin alpha cardiac muscle 1 Enzyme 0.046 1.26
mQ9R0K7 AT2B2 Plasma membrane calcium transporting ATPase 2 Transporter 0.005 1.25
mP11499 HS90B Heat-shock protein HSP 90 Other 0.006 1.21
mQ80W21 GSTM7 Glutathione S transferase Mu 7 Enzyme 0.041 1.18
mQ9D0J8 PTMS Parathymosin Other 0.030 1.15
mQ6GSS7 H2A2A Histone H2A type 2 A Other 0.031 1.14
mP02088 HBB1 Hemoglobin subunit beta 1 Transporter 0.002 1.14
mP68254 1433T 14 3 3 protein theta Other 0.002 1.14
mQ9D6F9 TBB4A Tubulin beta 4 chain Other 0.019 1.13
mQ99LX0 PARK Protein DJ 1 Enzyme 0.026 1.12
mP20029 GRP78 78 kDa glucose-regulated protein Other 0.002 1.11
mP00920 CAH2 Carbonic anhydrase 2 Enzyme 0.030 1.10
mQ6PHZ2 KCC2D Ca2þ calmodulin dep protein kinase type II D chain Kinase 0.019 1.10
mP63268 ACTH Actin gamma enteric smooth muscle Other 0.026 1.10
mP17183 ENOG Gamma enolase Enzyme 0.040 1.10
.O35660 GSTM6 Glutathione S transferase Mu 6 Enzyme 0.001 1.10
.P70696 H2B1A Histone H2B type 1 A Other 0.042 1.10
.Q61990 PCBP2 Poly rC binding protein 2 Other 0.007 1.10
.P15532 NDKA Nucleoside diphosphate kinase A Kinase 0.030 1.11
.P28184 MT3 Metallothionein 3 Other 0.038 1.12
.Q9D1G1 RAB1B Ras related protein Rab 1B Enzyme 0.001 1.12
.P09041 PGK2 Phosphoglycerate kinase 2 Kinase 0.026 1.13
.O70456 1433S 14 3 3 protein sigma Other 0.024 1.13
.P21550 ENOB Beta enolase Enzyme 0.009 1.13
.Q62420 SH3G2 Endophilin A1 Enzyme 0.045 1.13
.P08553 NFM Neurofilament medium polypeptide Other 0.012 1.14
.P62827 RAN GTP-binding nuclear protein Ran Enzyme 0.019 1.14
.Q63810 CANB1 Calcineurin subunit B type 1 Phosphatase 0.035 1.15
.Q9WV27 AT1A4 Naþ /Kþ transporting ATPase subunit alpha 4 Transporter 0.035 1.17
.P06837 NEUM Neuromodulin Other 0.012 1.18
.Q61598 GDIB Rab GDP dissociation inhibitor beta Other 0.012 1.18
.Q9CQV8 1433B 14 3 3 protein alpha Other 0.019 1.18
.P31001 DESM Desmin Other 0.019 1.19
.P31786 ACBP Acyl CoA-binding protein Other 0.046 1.19
.P26443 DHE3 Glutamate dehydrogenase 1 mitochondrial Enzyme 0.023 1.19
.P28652 KCC2B Ca2þ calmodulin dep protein kinase type II chain Kinase 0.046 1.20
.Q9R0P9 UCHL1 Ubiquitin carboxyl terminal hydrolase isozyme L1 Peptidase 0.017 1.21
.P05202 AATM Aspartate aminotransferase mitochondrial Enzyme 0.001 1.21
.P63328 PP2BA Ser/Thr protein phosphatase 2B catalytic subunit a Phosphatase 0.004 1.22
.Q01768 NDKB Nucleoside diphosphate kinase B Kinase 0.047 1.22
.O35737 HNRH1 Heterogeneous nuclear ribonucleoprotein H Other 0.014 1.23
.P50516 VATA V-type proton ATPase catalytic subunit A Transporter 0.030 1.23
.Q8BHC1 RB39B Ras related protein Rab 39B Enzyme 0.004 1.24
.P09671 SODM Superoxide dismutase Mn mitochondrial Enzyme 0.017 1.26
.O08709 PRDX6 Peroxiredoxin 6 Enzyme 0.035 1.28
.P02104 HBE Hemoglobin subunit epsilon Y2 Transporter 0.030 1.29
.P61750 ARF4 ADP ribosylation factor 4 Enzyme 0.012 1.30
.P46660 AINX Alpha internexin Other 0.004 1.32
.P16627 HS71L Heat shock 70 kDa protein 1 l Other 0.023 1.38
.P97427 DPYL1 Dihydropyrimidinase related protein 1 Enzyme 0.009 1.45
.P08249 MDHM Malate dehydrogenase mitochondrial Enzyme 0.005 1.45
.Q9DB77 QCR2 Cytochrome b c1 complex subunit 2 mitochondrial Enzyme 0.030 1.47
.P14152 MDHC Malate dehydrogenase cytoplasmic Enzyme 0.003 1.47
Abbreviations: LC-MSE, liquid chromatography mass spectrometry; UniProt, UniProt accession code.
Cellular locations and molecular functions were assigned using Ingenuity Pathway Analysis Knowledge Base. The ratio was calculated as in the legend for Table 3.
Increased and decreased levels of analytes are represented by green and red arrows respectively.
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have shown that immune system perturbations occur in
type 2 diabetes mellitus,23 as well as in psychiatric and
neurodegenerative disorders, including schizophrenia,17
depression24 and Alzheimer’s disease.25 However, the
overlap of immune-related molecules across these conditions
with the db/db mice model is not surprising given that these
pathways are affected in a variety of diseases. In the case of
the db/db mouse, the observed perturbations in immune
system molecules could be due to the high circulating levels of
leptin, as this hormone can also act as pro-inflammatory
adipokine.26 Leptin has been tested as a possible treatment
for autoimmune and/or inflammatory diseases in a recent
study27 and preclinical studies have shown that the depres-
sion-like symptoms in the chronic stress and social defeat rat
models was associated with lower serum leptin concentra-
tions, and the behavioral effects could be reversed by
systemic leptin administration.28
Comparison of circulating molecules changing in the db/db
mouse model to those identified in our previous study of first
onset schizophrenia patients shows that 12 proteins were
altered in common and 6 of these showed the same
directional changes (insulin, serum amyloid P, interleukin
18, serum glutamic-oxaloacetic transaminase, apolipoprotein
A1 and epidermal growth factor).17 In addition, seven
circulating proteins (insulin, serum glutamic-oxaloacetic
transaminase, prolactin, cystatin C, stem cell factor, macro-
phage colony-stimulating factor and beta-2 microglobulin)
were changed in common between the db/db mouse and the
acute PCP rat model of schizophrenia, using the same
molecular profiling platform.29 Taken together, these findings
suggest that the db/db model shows an overlap of molecular
profiles with schizophrenia and other psychiatric or neuro-
degenerative disorders.
The most novel findings of the current study involved the
identification of changes in brain proteins as these have not
been described previously in association with this model.
Consistent with the effects on behavior seen in the db/db
mice,13,14 we identified multiple proteins that were altered in
brain tissues extracted from db/db mice compared with control
mice. The finding that more proteins were altered in the
hippocampus of the db/db mouse is consistent with the
reported effects on cognition and learning in this model. In line
with this, we found changes in three members of the 14-3-3
protein family in db/db mouse hippocampi. These proteins are
highly conserved and have an important role in neurodevelop-
ment due to their involvement in cellular processes, such as
cell signalling, growth and apoptosis.30 Also, perturbations in
these proteins have been found in schizophrenia, autism,
bipolar disorder and in subjects with impaired sensory motor
gating and memory.30,31 The latter finding is consistent with
the impairments seen in paired-pulse inhibition in the db/db
mice. Furthermore, our findings of altered expression of
Ca2þ -regulatory proteins, such as CAMK2B, CAMK2D and
calcineurin subunit B type 1, are in line with studies that
identified impaired cardiac function in db/db mice through
suppression of Ca2þ permeability.32 This also supports the
possibility that the defect found in the db/db mice is systemic,
with effects seen in both the brain and periphery.
Fewer proteomic changes were found in the frontal cortex
region of the db/db mice using the LC-MSE proteomic profiling
approach. However, in silico analysis of the 13 significantly
altered proteins resulted in identification of ‘neurological
disorder’ as the top associated disease and ‘Parkinson’s
signalling’ as the top canonical pathway. Again, this indicated
potential effects on dopaminergic pathways as seen most
notably in Parkinson’s disease and schizophrenia. In addition,
one of the brain proteins found to be altered in both the db/db
and the acute PCP rodent model described above,29 was
protein DJ-1 (also known as PARK7). DJ-1 is an oxidative
stress response protein that defends cells against reactive
oxygen species. Furthermore, CAMK2A was found to be
changing in the db/db mice as found in our previous study of
the acute PCP model of schizophrenia.29 Previous studies
have also found perturbed expression of these proteins in
post-mortem frontal cortex tissues from schizophrenia
patients33,34 as well as in disorders associated with effects
on learning and memory.35–37
One limitation of this study was the small numbers of
animals used to generate the data. However, we have
attempted to compensate for this through comparison of the
findings with those in the literature on the same mouse model,
the acute PCP model, drug-naive schizophrenia subjects and
on protein pathways altered in schizophrenia post-mortem
brain tissues. Nevertheless, these studies require repetition in
independent cohorts of db/db mice, and future studies should
attempt to further explore the specificity of the effects through
comparison with other animal models and other human
psychiatric and neurodegenerative diseases. Also, the db/db
mouse has been mainly used in type 2 diabetes research, and
it should be noted that the alterations in central nervous
system could result from the change of leptin receptor
signalling in the brain or though complications of diabetes
itself.
In conclusion, this study resulted in the identification of
novel central nervous system proteomic alterations that
link the metabolic abnormalities found in the db/db mouse
model to neurodegenerative and neuropsychiatric diseases.
Figure 2 In silico functional analysis of protein changes in the hippocampus
of db/db mice. UniProt accession codes were uploaded into the Ingenuity
Pathway Analysis Knowledge Base to determine the most over-represented
networks and canonoical pathways associated with the data. Straight lines¼ direct
connections; dotted lines¼ indirect connections; green colour¼ increased; red
colour¼ decreased.
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This has laid the ground work for further studies of the db/db
mouse model in testing whether treatment with drugs such as
antidepressants, antipsychotics or anti-diabetic compounds
has a positive effect on the behaviors and brain proteome
changes observed. Sharma et al.14 have already carried out a
study which showed that treatment of db/db mice with
rosiglitazone could affect depression measures, but this had
no effect on readouts for psychosis-like behaviours. Taken
together with previous investigations on the behavioural
effects in this model, the current study supports the use of
the db/db mouse as a potential preclinical model for
schizophrenia and potentially other psychiatric or neurode-
generative disorders. Also, the combined use of this model
with incorporation of high throughput assays for the plasma
and brain molecular candidates identified here would poten-
tially offer a useful novel tool for drug discovery, with a focus
on the metabolic aspects of mental disorders and/or the
psychopathology associated with diabetes.
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